SUVARI TRICIA BORGA 4
4 · Global Blood Therapeutics, Inc. · Filed Aug 3, 2022
Insider Transaction Report
Form 4
SUVARI TRICIA BORGA
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2022-08-01+6,145→ 41,728 total - Exercise/Conversion
Restricted Stock Units
2022-08-01−3,020→ 9,060 total→ Common Stock (3,020 underlying) - Tax Payment
Common Stock
2022-08-01$32.40/sh−2,126$68,882→ 39,602 total - Exercise/Conversion
Restricted Stock Units
2022-08-01−3,125→ 3,125 total→ Common Stock (3,125 underlying)
Footnotes (5)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Reflects a decrease of 70 shares of the Issuer's Common Stock previously reported as acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F3]Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,145 shares of Common Stock underlying the Reporting Person's RSUs.
- [F4]The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- [F5]The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.